# CJC-1295

A 30-amino-acid version of sermorelin, modified to bind a blood protein so it lasts for days. Small studies show it raises growth hormone. Its only body-fat trial was halted in 2006 after a participant died.

Also called: DAC:GRF, Modified GRF 1-29 (the version without DAC)
Source page: https://peplogue.com/peptides/cjc-1295/
Updated: 2026-10-22. Not medical advice.

## How it works

- Where it acts: Growth-hormone-releasing hormone receptors. The DAC version binds a blood protein, so it lasts about a week.
- What it changes: A long rise in growth hormone and IGF-1.
- What people notice: In small studies, IGF-1 stayed raised for more than a week after one injection. Flushing and a faster heart rate were reported.

## What the evidence shows

- **Muscle gain, fat loss, anti-aging**: Lab only. Its one controlled body-fat trial, in 192 people with HIV, never reported results.
- **Raises growth hormone and IGF-1**: Early. In two small placebo-controlled studies in healthy adults in 2006, growth hormone rose 2 to 10 times for six days or more, and IGF-1 rose 1.5 to 3 times for 9 to 11 days.

## Side effects and risks

- serious: A participant in the 2006 phase 2 trial died. The treating physician attributed the death to undiagnosed heart disease, not the drug, but development ended.
- serious: FDA cites serious adverse events, including a faster heart rate and widened blood vessels, and a risk of immune reactions.
- unknown: Raises IGF-1 for days at a time. Long-term effects are unstudied.

Who should avoid it: Anyone with heart disease or active cancer, and athletes.

## How it has been given in studies

Injected under the skin once a week or every two weeks, dosed by body weight, for two or three doses. The short-acting version sold without DAC has no published human trials.

## Legal status

- United States: undefined. Its nominations were withdrawn, and in December 2024 FDA advisers voted against allowing any form of it in compounding. It is not on the list pharmacies may compound from.
- European Union: undefined
- Spain: undefined. Research peptide. No authorised medicine in Spain (no CIMA entry found). Not lawful to sell to the public as a medicine, food or cosmetic.
- Germany: undefined. Not approved in Germany. Named in the AntiDopG doping annex (GHRH); unapproved sale is a crime under the AMG.
- France: undefined. No French authorisation found. Not named by ANSM, but its Jul 2026 alert says peptides bought outside the official circuit are illegal.
- Italy: undefined. No Italian authorisation found. On the WADA banned list (GHRH analogues). Sold online as research vials; not a lawful medicine.
- Netherlands: undefined. No Dutch marketing authorisation. Sold online as 'research' product, which IGJ says is illegal for medicines. Banned in sport (WADA S2).
- United Kingdom: undefined
- Canada: undefined. Named in a 2025 Health Canada advisory on unauthorized injectable peptides.
- Australia: undefined. Schedule 4 and Appendix D of the Poisons Standard: possession without authority is illegal.

## Questions people ask

**What is the difference between CJC-1295 with and without DAC?**

The DAC version binds a blood protein, so it lasts about a week, and in small studies IGF-1 stayed raised for more than a week after one injection. The short-acting version sold without DAC, also called modified GRF 1-29, has no published human trials.

**Why is CJC-1295 stacked with ipamorelin?**

Users report deeper sleep and better recovery, usually when it is stacked with ipamorelin. These are recurring forum themes, not trial results.

**What are the side effects of CJC-1295?**

Users report flushing and a pounding heart just after injecting, water retention, tingling or numb hands and headaches. FDA cites serious adverse events, including a faster heart rate and widened blood vessels, and a risk of immune reactions.

**Did someone die in a CJC-1295 trial?**

Yes. A participant in the 2006 phase 2 trial died; the treating physician attributed the death to undiagnosed heart disease, not the drug, but development ended.

**Is CJC-1295 legal?**

In the US it is not on the list pharmacies may compound from, and in December 2024 FDA proposed keeping every form of it out of compounding. In Australia possession without authority is illegal, and Health Canada named it in a 2025 advisory.

## Sources

- Teichman et al. 2006: CJC-1295 in healthy adults: https://zenodo.org/records/1083962
- FDA: bulk substances that may present significant safety risks: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- aidsmap: lipodystrophy study halted after patient death (Jul 2006): https://www.aidsmap.com/news/jul-2006/lipodystrophy-study-halted-after-patient-death
- FDA briefing: CJC-1295 and compounding (Dec 2024): https://www.fda.gov/media/183583/download
- Finnrick: vendor test counts: https://www.finnrick.com/